PCR Kit Developed for Detection of Q-fever Pathogen
|
By LabMedica International staff writers Posted on 17 Oct 2019 |
|
Image: The BioPhotometer 6131 spectrophotometer/fluorometer (Photo courtesy of Eppendorf).
Coxiella burnetii is an obligate intracellular bacterium that causes Q fever in animals and humans. The infection results from inhalation of a spore-like small-cell variant, and from contact with the milk, urine, feces, vaginal mucus or semen of infected animals.
Incubation period is usually two to three weeks. The most common manifestation is flu-like symptoms with abrupt onset of fever, malaise, profuse perspiration, severe headache, muscle pain, joint pain, loss of appetite, upper respiratory problems, dry cough, pleuritic pain, chills, confusion, and gastrointestinal symptoms, such as nausea, vomiting, and diarrhea. About half of infected individuals exhibit no symptoms.
Virologists at the Institute of Laboratory Diagnostics and Veterinary and Sanitary Expertise (Kiev, Ukraine) developed a confirmatory polymerase chain reaction (PCR) for C. burnetii for diagnosis in Ukraine. The PCR assay targeted the outer membrane-associated gene com1 in C. burnetii. Oligonucleotide primers were selected that amplify a 689-bp DNA fragment of the com1 gene. The optimization of PCR amplification was accomplished by adjusting Mg2+ and dNTP concentrations in the PCR mixture, and testing different annealing temperatures.
Specificity of the designed primers was evaluated using a panel of DNA samples of various pathogens that were regarded as potentially present in the samples that would be tested. The specificity was evaluated using reference control DNA C. burnetii#5131 and C. burnetii Gritta strains. Concentration and purity of all DNA were evaluated using the spectrophotometer/fluorometer BioPhotometer 6131.
The assay proved highly sensitive and specific to C. burnetii DNA detection with a limit of detection (LOD) of 0.37 pg/μL. Reproducibility of the test was verified by comparing the PCR results with those of a different PCR protocol and qPCR. The method showed no cross-reactivity with genomic DNAs of eight pathogens. The authors concluded that the diagnostic kit Coxiella burnetii-PCR-TEST has high sensitivity and specificity can serve as a valid diagnostic tool for C. burnetii detection in biological samples. The study was published on September 19, 2019, in the journal Vector-Borne and Zoonotic Diseases.
Related Links:
Institute of Laboratory Diagnostics and Veterinary and Sanitary Expertise
 assay.jpg)
Incubation period is usually two to three weeks. The most common manifestation is flu-like symptoms with abrupt onset of fever, malaise, profuse perspiration, severe headache, muscle pain, joint pain, loss of appetite, upper respiratory problems, dry cough, pleuritic pain, chills, confusion, and gastrointestinal symptoms, such as nausea, vomiting, and diarrhea. About half of infected individuals exhibit no symptoms.
Virologists at the Institute of Laboratory Diagnostics and Veterinary and Sanitary Expertise (Kiev, Ukraine) developed a confirmatory polymerase chain reaction (PCR) for C. burnetii for diagnosis in Ukraine. The PCR assay targeted the outer membrane-associated gene com1 in C. burnetii. Oligonucleotide primers were selected that amplify a 689-bp DNA fragment of the com1 gene. The optimization of PCR amplification was accomplished by adjusting Mg2+ and dNTP concentrations in the PCR mixture, and testing different annealing temperatures.
Specificity of the designed primers was evaluated using a panel of DNA samples of various pathogens that were regarded as potentially present in the samples that would be tested. The specificity was evaluated using reference control DNA C. burnetii#5131 and C. burnetii Gritta strains. Concentration and purity of all DNA were evaluated using the spectrophotometer/fluorometer BioPhotometer 6131.
The assay proved highly sensitive and specific to C. burnetii DNA detection with a limit of detection (LOD) of 0.37 pg/μL. Reproducibility of the test was verified by comparing the PCR results with those of a different PCR protocol and qPCR. The method showed no cross-reactivity with genomic DNAs of eight pathogens. The authors concluded that the diagnostic kit Coxiella burnetii-PCR-TEST has high sensitivity and specificity can serve as a valid diagnostic tool for C. burnetii detection in biological samples. The study was published on September 19, 2019, in the journal Vector-Borne and Zoonotic Diseases.
Related Links:
Institute of Laboratory Diagnostics and Veterinary and Sanitary Expertise
New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Latest Technology News
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
- AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
- AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
- AI Model Achieves Breakthrough Accuracy in Ovarian Cancer Detection
- Portable Biosensor Diagnoses Psychiatric Disorders Using Saliva Samples
- Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
- Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
- Viral Biosensor Test Simultaneously Detects Hepatitis and HIV
- Acoustofluidic Device to Transform Point-Of-Care sEV-Based Diagnostics
- AI Algorithm Assesses Progressive Decline in Kidney Function
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read more
Hematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Immunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read more
Microbiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read more
Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
Pathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read more
AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
Technology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
Industry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more
